JPRN-UMIN000034613尚未招募未知
The Exploratory Study about Efficacy and Safety of Ninjin'yoeito for Fatigue and Malaise Expressed in Postoperative Patients with Colorectal Cancer - The Exploratory Study about Efficacy and Safety of Ninjin'yoeito in Postoperative Patients with Colorectal Cancer
niversity of Toyama0 个研究点目标入组 15 人开始时间: 2018年11月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 80years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with active other cancers 2) Patients with severe complications (such as liver disease, renal disease, heart disease, blood disease or metabolic disease) or mental disease 3) Patients taking drugs banned in this study or Ninjin'yoeito within 4 weeks before the start of the study 4) Patients who have a history of allergies to traditional Chinese medicine
研究者
相似试验
进行中（未招募）
不适用
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe DiseasePompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2015-000584-14-Outside-EU/EEAGenzyme Corporation Inc4
进行中（未招募）
不适用
Immune Tolerance Induction StudyPompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2015-000583-34-Outside-EU/EEAGenzyme Corporation Inc9
进行中（未招募）
1 期
An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature EjaculatioMedDRA version: 14.1 Level: PT Classification code 10036596 Term: Premature ejaculation System Organ Class: 10037175 - Psychiatric disordersPremature EjaculationEUCTR2013-001650-94-GBAllergan Limited59
已完成
不适用
Exploratory research of the efficacy and safety with the enamel matrix derivative for anterior cruciate ligament reconstructioanterior cruciate ligament injuryJPRN-UMIN000015497Hiroshima University Hospital19
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864EUCTR2018-003866-14-ESApexigen, Inc.174